public comment period closes June 29, 2026 - large-scale 503B compounding pathway under active regulatory review 503A patient-specific compounding: operates under a separate legal framework independent of shortage-list status
239,240 This activation increases the expression of proinflammatory cytokines and adhesion molecules, contributing to oxidative stress, inflammation, and vascular dysfunction
Bonnet F, Scheen AJ (2017) Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Quick Contact Basic contact form
Although emerging data suggest potential protective effects through improved metabolic stability and reduced inflammation, definitive proof is lacking
Regardless of whether this PFC dysfunction is a cause or consequence of either obesity or AUD, its implications for treatment adherence and persistence are clear: whether in weight loss for obesity or reducing alcohol consumption in the context of AUD, more cognitive control and behavioral inhibition is better than less
